Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10460-10472

  Zhu, Shicong ^a   Wang, Zhihua ^a   Li, Zijian ^a,b   Peng, Hongling ^a   Luo, Yunya ^a   Deng, Mingyang ^a   Li, Ruijuan ^a   Dai, Chongwen ^a   Xu, Yunxiao ^a   Liu, Sufang ^a   Zhang, Guangsen ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Antitumor activities; Icaritin; IL6 JAK2 STAT3 signaling; Multiple myeloma

Indexed keywords

CASPASE 3; CASPASE 9; ICARIIN; ICARITIN; IMMUNOGLOBULIN E; INTERLEUKIN 6; JANUS KINASE 2; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; STAT3 PROTEIN; UNCLASSIFIED DRUG; FLAVONOID; JAK2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG SCREENING; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE;

ANIMALS; FEMALE; FLAVONOIDS; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929590465     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3399     Document Type: Article

References (45)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008; 111:2962-72.
2. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111:2516-20.
3. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB, Sung B. Molecular targets of nutraceuticals derived from dietary spices: potential role in suppression of inflammation and tumorigenesis. Exp Biol Med (Maywood). 2009; 234:825-849.
4. Banerjee Mustafi S, Chakraborty PK, Raha S. Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS one. 2010; 5:e8719.
5. Sarkar FH, Li Y, Wang Z, Kong D. Cellular signaling perturbation by natural products. Cell Signal. 2009; 21:1541-1547.
6. Wang Z, Wang H, Wu J, Zhu D, Zhang X, Ou L, Yu Y, Lou Y. Enhanced co-expression of beta-tubulin III and choline acetyltransferase in neurons from mouse embryonic stem cells promoted by icaritin in an estrogen receptor-independent manner. Chem Biol Interact. 2009; 179:375-385.
7. Wo YB, Zhu DY, Hu Y, Wang ZQ, Liu J, Lou YJ. Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J Cell Biochem. 2008; 103:1536-1550.
8. Huang J, Yuan L, Wang X, Zhang TL, Wang K. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci. 2007; 81:832-840.
9. Li Q, Huai L, Zhang C, Wang C, Jia Y, Chen Y, Yu P, Wang H, Rao Q, Wang M, Wang J. Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways. Int J Hematol. 2013; 97:617-23.
10. Zhu JF, Li Zj, Zhang Gs, Meng K, Kuang Wy, Li J, Zhou Xf, Li Rj, Peng Hl, Dai Cw, Shen JK, Gong Fj, Xu Yx, Liu Sf. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PloS one. 2011; 6:e23720.
11. Wang ZQ, Lou YJ. Proliferation-stimulating effects of Icaritin and desmethylicaritin in MCF-7 cells. Eur J Pharmacol. 2004; 504:147-153.
12. Huang X, Zhu D, Lou Y. A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol. 2007; 564:26-36.
13. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y, Ueki A. Estrogen receptors in human myeloma cells. Cancer Research. 2000; 60:1434-1441.
14. Kyle RA. Multiple myeloma and other plasma cell disorder. In: Hoffman R, Benz Jr. EB, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology: Basic and Principles and Practice, 3rd ed. New York: Churchill Livingstone, Inc.; 2000; p1398-1416.
15. Jantunen E, Laakso M. Bisphosphonates in multiple myeloma: current status; future perspectives. Br J Haematol. 1996; 93:501-6.
16. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002; 8:945-954.
17. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol. 2003; 171:3863-3871.
18. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10:105-15.
19. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995; 85:863-72.
20. Liu SQ, Ma Z, Cai HL, Li Q, Rong WY, Kawano M. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells. Eur J Haematol. 2010; 84:137-44.
21. Zhu J, Wang M, Yu Y, Qi H, Han K, Tang J, Zhang Z, Zeng Y, Cao B, Qiao C, Zhang H, Hou T, Mao X. A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma. Oncotarget. 2015; 6:185-95.
22. Podar K, Hideshima T, Chauhan D, Anderson KC. Targeting signalling pathways for the treatment of multiple myeloma. Expert opinion on therapeutic targets. 2005; 9:359-381.
23. Wagner V, Hose D, Seckinger A, Weiz L, Meißner T, Rème T, Breitkreutz I, Podar K, Ho AD, Goldschmidt H, Krämer A, Klein B, Raab MS. Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1. Oncotarget. 2014; 5:10237-50.
24. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998; 18:753-61.
25. Ewen ME. Where the cell cycle and histones meet. Genes Dev. 2000; 14:2265-70.
26. Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997; 13:261-91.
27. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood. 1991; 77:587-93.
28. Ramakrishnan V, Painuly U, Kimlinger T, Haug J, Rajkumar SV, Kumar S. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Leukemia. 2014; 28:1519-28.
29. Oancea M, Mani A, Hussein MA, Almasan A. Apoptosis of multiple myeloma. Int J Hematol. 2004; 80:224-31.
30. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116:205-19.
31. Spets H, Strömberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6) -induced growth and survival. Eur J Haematol. 2002; 69:76-89.
32. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988; 332:83-5.
33. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:a Leading role for STAT3. Nat Rew Cancer. 2009; 9:798-809.
34. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell. 2009; 15:79-80.
35. Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S, Chang CH, Goldenberg DM. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood. 2010; 115:5180-90.
36. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernández-Luna JL, Nuñez G, Dalton WS, Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999; 10:105-15.
37. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, et al. Gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer cell. 2009; 15:91-102.
38. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer cell. 2009; 15:103-13.
39. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, et al. Over-expression of CKSB activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010; 1:22-33.
40. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, et al. Constitutive Stat3 activity up- regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21:2000-2008.
41. Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001; 98:428-35.
42. Mckenna RW, Kyle RA, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon: IARC; 2008; p200-213.
43. Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S, Estrov Z, Talpaz M, Aggarwal BB. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood. 2004; 103:3175-84.
44. Kuiper GG, Gustafsson JA. The novel estrogen receptor- beta subtype: potential role in the cell-and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 1997; 410:87-90.
45. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997; 138:863-70.